---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-002874"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T02:39:48.667550+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rigel reports prelim Q4 total revenue $57.6M, guides FY2025 rev $200-210M

## Summary
- Q4 2024 total revenue $57.6M vs $35.8M Q4 2023; net product sales $46.5M.
- TAVALISSE net sales $31.0M, REZLIDHIA $7.4M, GAVRETO $8.1M (launched June 2024).
- Full-year 2024 total revenue $179.3M; cash & equivalents $77.3M at year-end.
- 2025 guidance: total revenue $200-210M; expects positive net income for the year.
- R289 granted Orphan Drug designation by FDA for MDS; Phase 1b enrollment ongoing.

## SEC filing metadata
- accession: 0001104659-25-002874
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465925002874/0001104659-25-002874-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465925002874/tm253048d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-002874
- JSON: https://secwatch.observer/filing/0001104659-25-002874.json
- Plain text: https://secwatch.observer/filing/0001104659-25-002874.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.